A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now considered the standard of care. A 2024 phase 3 trial reported a median 39.1 months without cancer growth on osimertinib versus 5.6 months on placebo. The FDA approved the use in this setting on Sept. 25, 2024.

The LAURA phase 3 trial tested osimertinib vs. placebo in patients whose disease had not progressed after concurrent or sequential chemoradiation. Osimertinib significantly extended progression-free survival and reduced the risk of cancer spreading to the brain compared to placebo.

Who is eligible for Tagrisso?

Under the FDA label, the therapy is for adult patients with locally advanced, unr

See Full Page